Galderma Shares Plunge After FDA Rejects Botox Rival Relfydess
AbbVie's Botox franchise faces reduced near-term competition in the U.S. after the FDA rejected Galderma's Relfydess. This secures Botox's market dominance.
- ▲ Relfydess rejection removes a competitor
- ▼ Other competitors may still threaten Botox
- ▼ FDA could approve other Botox alternatives soon
▼ Show FAQ (3) ▲ Hide FAQ
Why is AbbVie benefiting from this news?
AbbVie's Botox is the dominant product in the U.S. medical aesthetics market. The removal of a near-term competitor reducescompetitive pressure, potentially supporting Botox's market share and pricing power.
How much market share does Botox have?
Botox holds a commanding lead in the U.S. neurotoxin market, often estimated above 70%. The absence of a new entrant helps maintain that share in the short term.
Could another competitor still threaten AbbVie?
Yes, other companies like Revance Therapeutics and Evolus have their own neurotoxin products either on the market or in development. However, none have matched Botox's scale yet, and the rejection of Relfydess temporarily reduces the immediate threat.